119th Congress · introduced in the House · Mar 25, 2025
John W. Walsh Alpha-1 Home Infusion Act of 2025
Official title from Congress.gov
Latest action (Mar 25, 2025): Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
View on Congress.govPolicy area: Health
Congressional Research Service summary, version: Introduced in House (Mar 25, 2025)
John W. Walsh Alpha-1 Home Infusion Act of 2025
This bill provides for Medicare coverage of treatment for alpha-1 antitrypsin (AAT) deficiency (a protein deficiency that raises the risk of lung and other diseases). Specifically, the bill provides for coverage of at-home augmentation therapy for beneficiaries with emphysema as a result of severe hereditary AAT deficiency. Treatment must be provided through qualified home infusion therapy suppliers; beneficiaries must be under the care of a physician, nurse practitioner, or physician assistant.
Includes amendment, cloture, and procedural votes. Each is labeled with its exact question; only a passage question is a vote to pass the bill.
No recorded roll calls on this bill in coverage.
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Introduced in House
Introduced in House
Actions from Congress.gov, newest first.
LD-2 reports whose issue descriptions explicitly cite this bill (bill type and number validated against Congress.gov records). A citation does not establish the client's position or any contact with a member.
Loading lobbying reportsCoverage: reports for 2025 onward, posted Jan 1, 2025 through Oct 23, 2026.
11 citations.
GRIFOLS SHARED SERVICES NORTH AMERICA INC · lobbying firm or registrant: GRIFOLS SHARED SERVICES NORTH AMERICA, INC.
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 16, 2026 · issue area: Health Issues
$360,000
Spent on own lobbying
…IG) to patients with primary immune deficiency diseases (rare genetic disorders that impair the immune system and increase vulnerability for other infections). H.R. 2343 John W. Walsh Alpha‑1 Home Infusion Act of 2025;Provides Medicare coverage for at‑home augmentation therapy for beneficiaries with emphysema resulting from sev…
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
GRIFOLS SHARED SERVICES NORTH AMERICA INC · lobbying firm or registrant: GRIFOLS SHARED SERVICES NORTH AMERICA, INC.
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 17, 2026 · issue area: Health Issues
$370,000
Spent on own lobbying
…clude treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) and multifocal motor neuropathy, in addition to primary immune deficiency diseases. H.R. 2343 John W. Walsh Alpha‑1 Home Infusion Act of 2025;Provides Medicare coverage for at‑home augmentation therapy for beneficiaries with emphysema resulting from sev…
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
GRIFOLS SHARED SERVICES NORTH AMERICA INC · lobbying firm or registrant: GRIFOLS SHARED SERVICES NORTH AMERICA, INC.
2026 Q1 report (Jan 1, 2026 – Mar 31, 2026) · posted Apr 16, 2026 · issue area: Health Issues
$480,000
Spent on own lobbying
…clude treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) and multifocal motor neuropathy, in addition to primary immune deficiency diseases. H.R. 2343 John W. Walsh Alpha‑1 Home Infusion Act of 2025;Provides Medicare coverage for at‑home augmentation therapy for beneficiaries with emphysema resulting from sev…
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
GRIFOLS SHARED SERVICES NORTH AMERICA, INC. · lobbying firm or registrant: HOGAN LOVELLS CADWALADER US LLP (FKA HOGAN LOVELLS US LLP)
2025 Q4 report (Oct 1, 2025 – Dec 31, 2025) · posted Jan 20, 2026 · issue area: Health Issues
$80,000
Paid to lobbying firm
…legislation to provide rebate phase-in for plasma-derived therapies under the Medicare Part D program. H.R. 1143, Medicare IVIG Access Enhancement Act of 2025. H.R. 2343 , John W. Walsh Alpha-1 Home Infusion Act of 2025. H.R. 2172, Preserving Patient Access to Home Infusion Act. Issues related to the implementation of P.L. 117-…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
GRIFOLS SHARED SERVICES NORTH AMERICA INC · lobbying firm or registrant: GRIFOLS SHARED SERVICES NORTH AMERICA, INC.
2025 Q4 report (Oct 1, 2025 – Dec 31, 2025) · posted Jan 18, 2026 · issue area: Health Issues
$470,000
Spent on own lobbying
…, legislation to provide rebate phase-in for plasma-derived therapies under the Medicare Part D program H.R. 1143, Medicare IVIG Access Enhancement Act of 2025 H.R. 2343 , John W. Walsh Alpha-1 Home Infusion Act of 2025 S. 1818 / H.R.3546, Prescription Drug Price Relief Act of 2025 S.1587 / H.R.3375, Fair Prescription Drug Pric…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
GRIFOLS SHARED SERVICES NORTH AMERICA INC · lobbying firm or registrant: GRIFOLS SHARED SERVICES NORTH AMERICA, INC.
2025 Q3 report (Jul 1, 2025 – Sep 30, 2025) · posted Oct 17, 2025 · issue area: Health Issues
$450,000
Spent on own lobbying
…, legislation to provide rebate phase-in for plasma-derived therapies under the Medicare Part D program H.R. 1143, Medicare IVIG Access Enhancement Act of 2025 H.R. 2343 , John W. Walsh Alpha-1 Home Infusion Act of 2025 H.R. 2172, Preserving Patient Access to Home Infusion Act S. 1818 / H.R.3546, Prescription Drug Price Relief…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
GRIFOLS SHARED SERVICES NORTH AMERICA, INC. · lobbying firm or registrant: HOGAN LOVELLS CADWALADER US LLP (FKA HOGAN LOVELLS US LLP)
2025 Q3 report (Jul 1, 2025 – Sep 30, 2025) · posted Oct 16, 2025 · issue area: Health Issues
$80,000
Paid to lobbying firm
…legislation to provide rebate phase-in for plasma-derived therapies under the Medicare Part D program. H.R. 1143, Medicare IVIG Access Enhancement Act of 2025. H.R. 2343 , John W. Walsh Alpha-1 Home Infusion Act of 2025. H.R. 2172, Preserving Patient Access to Home Infusion Act. Issues related to the implementation of P.L. 117-…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
GRIFOLS SHARED SERVICES NORTH AMERICA, INC. · lobbying firm or registrant: HOGAN LOVELLS CADWALADER US LLP (FKA HOGAN LOVELLS US LLP)
2025 Q2 report (Apr 1, 2025 – Jun 30, 2025) · posted Jul 16, 2025 · issue area: Health Issues
$80,000
Paid to lobbying firm
…legislation to provide rebate phase-in for plasma-derived therapies under the Medicare Part D program. H.R. 1143, Medicare IVIG Access Enhancement Act of 2025. H.R. 2343 , John W. Walsh Alpha-1 Home Infusion Act of 2025. H.R. 2172, Preserving Patient Access to Home Infusion Act. Issues related to the implementation of P.L. 117-…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
GRIFOLS SHARED SERVICES NORTH AMERICA INC · lobbying firm or registrant: GRIFOLS SHARED SERVICES NORTH AMERICA, INC.
2025 Q2 report (Apr 1, 2025 – Jun 30, 2025) · posted Jul 16, 2025 · issue area: Health Issues
$390,000
Spent on own lobbying
…, legislation to provide rebate phase-in for plasma-derived therapies under the Medicare Part D program H.R. 1143, Medicare IVIG Access Enhancement Act of 2025 H.R. 2343 , John W. Walsh Alpha-1 Home Infusion Act of 2025 H.R. 2172, Preserving Patient Access to Home Infusion Act S. 1818 / H.R.3546, Prescription Drug Price Relief…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
GRIFOLS SHARED SERVICES NORTH AMERICA, INC. · lobbying firm or registrant: HOGAN LOVELLS CADWALADER US LLP (FKA HOGAN LOVELLS US LLP)
2025 Q1 report (Jan 1, 2025 – Mar 31, 2025) · posted Apr 15, 2025 · issue area: Health Issues
$80,000
Paid to lobbying firm
…legislation to provide rebate phase-in for plasma-derived therapies under the Medicare Part D program. H.R. 1143, Medicare IVIG Access Enhancement Act of 2025. H.R. 2343 , John W. Walsh Alpha-1 Home Infusion Act of 2025. H.R. 2172, Preserving Patient Access to Home Infusion Act. Issues related to the implementation of P.L. 117-…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
GRIFOLS SHARED SERVICES NORTH AMERICA INC · lobbying firm or registrant: GRIFOLS SHARED SERVICES NORTH AMERICA, INC.
2025 Q1 report (Jan 1, 2025 – Mar 31, 2025) · posted Apr 11, 2025 · issue area: Health Issues
$360,000
Spent on own lobbying
…legislation to provide rebate phase-in for plasma-derived therapies under the Medicare Part D program. H.R. 1143, Medicare IVIG Access Enhancement Act of 2025. H.R. 2343, John W. Walsh Alpha-1 Home Infusion Act of 2025. H.R. 2172, Preserving Patient Access to Home Infusion Act. Issues related to the implementation of P.L. 117-1…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing